CPD module: monoclonal antibodies

After completing this module, you should be more aware of:

• the different ways monoclonal antibodies (MABs) can be used to tackle disease
• the types of conditions that respond to MABs
• how MABs are selected and prepared
• types of MAB modification and how this affects their properties
• the way that MABs are named under the INN programme
• changes to MAB naming following the implementation of 2021 revisions
• types of targets for MABs in cancers and autoimmune diseases
• MABs targeting CD receptors on B and T cells
• MABs targeting growth factor receptors
• MABs targeting programmed death-1 and programmed death ligand 1 receptors
• MABs targeting tumour necrosis factor
• how potential MAB side effects or adverse reactions illustrate the complexity of the immune system